Response Evaluation Criteria and Performance Scales

Article

In clinical studies, formal response criteria have been developed and have gained wide acceptance. The National Cancer Institute (NCI) has proposed and implemented newer standard response criteria called Response Evaluation Criteria in Solid Tumors (RECIST). In contrast, the World Health Organization (WHO) has a different standard for assessing response. Major differences between these guidelines are outlined below.

Recist: Definition of Response

In clinical studies, formal response criteria have been developed and have gained wide acceptance.

The National Cancer Institute (NCI) has proposed and implemented newer standard response criteria called Response Evaluation Criteria in Solid Tumors (RECIST).

In contrast, the World Health Organization (WHO) has a different standard for assessing response.

Major differences between these guidelines are outlined below.

Comparison of RECIST and WHO guidelines

Performance Scales

The Karnofsky performance index and WHO (Zubrod) scale are commonly used as proxy measures for quality of life.

Because they measure only one dimension of the construct, they would not be considered quality-of-life measures by today’s standards.

However, given their historic relevance and current high frequency of usage as proxy measures, we have included them here.

Karnofsky performance index and WHO (Zubrod) scale

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
Related Content